According to Zhitong Finance App, Unnamed Pharmaceutical (002581.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net loss attributable to shareholders of listed companies was 27.7041 million yuan; net loss attributable to shareholders of listed companies deducted 28.33 million yuan for non-recurring profit and loss; basic loss per share was 0.0420 yuan/share.
未名医药(002581.SZ)发一季度业绩，净亏损2770.41万元
Unnamed Pharmaceutical (002581.SZ) reported first-quarter results with a net loss of 27.7041 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.